Bristol Myers Squibb on Sunday announced that it has entered into a definitive merger agreement with cancer-focused biotech Mirati Therapeutics in a bid to grow its oncology franchise.
Tag Archive for: adagrasib
Sanofi appears to be considering a buyout of cancer drugmaker Mirati Therapeutics, according to Bloomberg reporting on Thursday, citing sources familiar with the matter.
The agency’s top five represent an eclectic mix of cancer, cardiovascular and rare disease drugs.
Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.
Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co.’s immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.
Mirati Therapeutics Inc.’s experimental drug that targets a specific genetic mutation helped about one third of a small subset of patients in a clinical trial whose lung cancer had spread to their brains, the company said on Monday.
